贝伐珠单抗联合化疗治疗晚期非鳞非小细胞肺癌的效果分析  

Efficacy analysis of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous nonsmall cell lung cancer

作　　者：洪菊培 曹洪刚[1] 沈福军 HONG Jupei;CAO Honggang;SHEN Fujun(Department of Oncology,The Third People’s Hospital of Yancheng,Yancheng 224000)

机构地区：[1]盐城市第三人民医院肿瘤科,江苏盐城224000

出　　处：《当代医药论丛》2021年第20期128-130,共3页

摘　　要：目的:探讨联用贝伐珠单抗和化疗治疗晚期非鳞非小细胞肺癌的效果。方法:选取2019年1月至2021年3月期间盐城市第三人民医院收治的65例晚期非鳞非小细胞肺癌患者作为研究对象。将这些患者分为常规组(n=33例)和研究组(n=32)。两组患者入院后,均对其进行化疗。在此基础上,为研究组患者加用贝伐珠单抗进行治疗。比较两组患者的临床疗效。结果:治疗后,研究组患者病情的控制率、客观缓解率均高于常规组患者,P<0.05;其中位总生存期、中位无进展生存期均长于常规组患者,P<0.05。在治疗期间,两组患者不良反应的发生率相比,P>0.05。结论:联用贝伐珠单抗和化疗治疗晚期非鳞非小细胞肺癌的效果较为理想,安全性较高。Objective:To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer.Methods:Sixty-five patients with advanced non-squamous non-small cell lung cancer admitted to The Third People’s Hospital of Yancheng from January 2019 to March 2021 were selected as the study subjects.These patients were divided into conventional group(n=33 cases)and study group(n=32 cases).After admission,patients in both groups received chemotherapy.On this basis,patients in the study group were treated with bevacizumab.The clinical efficacy of the two groups was compared.Results:After treatment,the control rate and objective remission rate of patients in the study group were higher than those in the conventional group,P<0.05;Median overall survival and median progression-free survival were longer than those in conventional group,P<0.05.During treatment,the incidence of adverse reactions in 2 groups was compared,P>0.05.Conclusion:Bevacizumab combined with chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer has an ideal effect and high safety.

关 键 词：晚期非鳞非小细胞肺癌 贝伐珠单抗 化疗 

分 类 号：R734[医药卫生—肿瘤]